A Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial of Probucol in Reducing the Risk of Recurrent Stroke in Patients With Symptomatic Intracranial and Extracranial Large-artery Stenosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:
• 40 years or older than 40 years; 2.Ischemic stroke or transient ischemic attack (TIA); 3.Within 7 days from onset to randomization; 4.Main intracranial or extracranial arteries supplying the ischemic event region are narrowed by more than 50%; 5.Informed consent signed.
Locations
Other Locations
China
The First Affliated Hospital of Wannan Medical College
RECRUITING
Wuhu
Time Frame
Start Date: 2024-06-15
Estimated Completion Date: 2026-10-31
Participants
Target number of participants: 5452
Treatments
Experimental: Probucol Group
The study drug should be started as soon as possible within 7 days after symptom onset.
Placebo_comparator: Placebo Probucol Group
The study drug should be started as soon as possible within 7 days after symptom onset.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Wannan Medical College
Collaborators: Beijing Tiantan Hospital